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A B S T R A C T
Background
Glaucoma is the leading cause of irreversible blindness. Minimally invasive surgical techniques, such as ab interno trabecular bypass
surgery, have been introduced to prevent glaucoma progressing.
Objectives
The main objective was to assess the results at two years of ab interno trabecular bypass surgery with Trabectome for open angle
glaucoma in comparison to conventional medical, laser, or surgical treatment in terms of efficacy and safety. A secondary objective was
to examine the effects of Trabectome surgery in people who have concomitant phacoemulsification in comparison to those who do not
have concomitant phacoemulsification.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 4), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to May
2016), EMBASE (January 1980 to May 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (
www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 12 May 2016.
Selection criteria
We included only randomised controlled trials (RCTs) of ab interno trabecular bypass surgery with Trabectome.
Data collection and analysis
We planned to have two review authors independently extract data from reports of included studies using a data collection form.
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Main results
One randomised controlled trial identified from ClinicalTrials.gov, NCT00901108, met the criteria for inclusion. This study has
subsequently been terminated. The ClinicalTrials.gov record indicates that the investigators plan to complete 12 months of follow-up
and analysis on 19 participants already recruited into the trial.
Authors’ conclusions
There is currently no high-quality evidence for the outcomes of ab interno trabecular bypass surgery with Trabectome for open angle
glaucoma. Properly designed RCTs are needed to assess the long-term efficacy and safety of this technique.
P L A I N L A N G U A G E S U M M A R Y
Minimally invasive surgery with Trabectome for glaucoma
What was the aim of this review?
The aim of this Cochrane Review was to learn if a Trabectome improves the surgical treatment of glaucoma. Cochrane researchers
collected and analysed all relevant studies to answer this question and found no completed studies.
Key messages
There are no data comparing Trabectome with other treatments.
What was studied in the review?
Glaucoma is the leading cause of irreversible blindness. In glaucoma the optic nerve at the back of eye is damaged, in many cases
because the pressure inside the eye is too high. Doctors can lower the eye pressure by surgery. The Trabectome is a device that could
help make this surgery less invasive, which may be safer than standard surgery.
What are the main results of the review?
The review authors did not find any completed studies.
How up-to-date is this review?
The review authors searched for studies published up to 12 May 2016.
B A C K G R O U N D
Description of the condition
Glaucoma is a chronic progressive optic neuropathy affecting up
to 4% of people by the age of 80 years (Burr 2007). It is the leading
cause of irreversible blindness, affecting 60million people globally
(Quigley 2006). This figure is expected to increase to 80 million
people by 2020. Open angle glaucoma (OAG) is the most com-
mon type, accounting for three-quarters of cases (Quigley 2006).
In one large population cohort, 1 in 6 people with OAG became
bilaterally blind (Peters 2013). The only proven way to prevent
vision loss is to reduce the pressure inside the eye (intraocular pres-
sure) over the long term (AGIS 2000; CNTG Study Group 1998;
Heijl 2002; Kass 2002). Approaches to reducing intraocular pres-
sure (IOP) include medical therapy, laser treatments, and surgery.
As commercially available eye drop preparations have a short-last-
ing effect, medical therapy requires eye drops to be instilled one
or more times daily for life. Adherence is very poor, even if use is
monitored (Friedman 2009; Okeke 2009). Conventional surgical
techniques such as trabeculectomy are associated with significant
risks, with more than 40% of patients developing perioperative
complications (Kirwan 2013; Lichter 2001), and 7% to 18% of
cases requiring re-operation (Gedde 2012; Kirwan 2013). These
techniques are therefore often reserved for disease that is progress-
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ing despite other treatments (King 2013).
Description of the intervention
A number of minimally invasive surgical techniques have recently
been developed with the aim of achieving long-term reduction
of IOP with a better safety profile than conventional surgery (
Francis 2011). Among them, ab interno trabecular bypass surgery
(also known as trabeculotomy ab interno and trabeculectomy ab
interno) with the Trabectome (NeoMedix, Tustin, California) is a
Food and Drug Administration (FDA) approved and CE marked
treatment.
How the intervention might work
The trabecular meshwork is the eye’s main site of resistance to
outflow of aqueous humour (Overby 2009). The Trabectome is
designed to selectively ablate a portion of the trabecularmeshwork,
enabling aqueous humour to have direct access to the canal of
Schlemm and thence the collector channels (Francis 2006). This
is intended to promote aqueous outflow, thereby reducing IOP.
Tissue ablation is performed electrosurgically using a 19.5-gauge
instrument, which is introduced into the eye via a 1.6-mm incision
in the cornea.
Why it is important to do this review
Consultationwith patients and healthcare professionals has identi-
fied a need for better treatments for glaucoma (James Lind Alliance
2013). Minimally invasive glaucoma procedures carry the possi-
bility of safe and effective long-term reduction of IOP, removing
concerns about permanent vision loss due to non-adherence to eye
drops. A single treatment may also be more acceptable to patients
than daily and indefinite self administration of eye drops. Initial
results of ab interno trabecular bypass surgery with the Trabec-
tomewere reported in 2005 (Minckler 2005). Post-market surveil-
lance data show that more than 4600 treatments were performed
between 2004 and 2013 at over 200 centres worldwide (Mosaed
2014; NeoMedix, on file). In light of the potential benefits for
patients and the widespread uptake of the technique, it is impor-
tant to critically evaluate the evidence for whether treatment with
the Trabectome is both efficacious and safe. Importantly, Trabec-
tome surgerymay be combinedwith phacoemulsification (cataract
surgery), a sight-restoring operation to remove the natural lens of
the eye when it has lost clarity. Since phacoemulsification itself
reduces IOP (Mansberger 2012), we planned specifically to ex-
amine the evidence for efficacy of Trabectome treatment in peo-
ple who have concomitant phacoemulsification in comparison to
those who do not have concomitant phacoemulsification.
O B J E C T I V E S
The main objective was to assess the results at two years of ab
interno trabecular bypass surgery with Trabectome for OAG in
comparison to conventional medical, laser, or surgical treatment
in terms of efficacy and safety. A secondary objective was to ex-
amine the effects of Trabectome surgery in people who have con-
comitant phacoemulsification in comparison to those who do not
have concomitant phacoemulsification.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only. We in-
cluded all study reports published in the English language (or
which have been translated into English), irrespective of their pub-
lication status. We planned to exclude within-person studies be-
cause of the potential for medical treatments, such as topical beta
blockers, used for one eye to influence the outcome in the other
eye (Piltz 2000).
Types of participants
Participants could have OAG of any type, including primary and
secondary OAG.We excluded closed angle glaucoma. As there are
no universally accepted criteria by which glaucoma may be de-
fined, we permitted studies to use their own definitions of glau-
coma (provided these were clearly stated). Participants with ocu-
lar hypertension, normal tension glaucoma, or possible glaucoma
(suspects for glaucoma) were also included. We applied no restric-
tions regarding location, setting, or demographic factors.
Types of interventions
The intervention was ab interno trabeculotomy performed with
the Trabectome (NeoMedix, Tustin, California). Although it is
possible to ablate a variable amount of the trabecular meshwork
(typically an arc of 40 degrees), and to vary the electrosurgical
power employed (Francis 2006), we did not apply any particular
inclusion or exclusion criteria around these or other treatment de-
livery parameters. The comparators were conventional glaucoma
treatment, whether using medical therapy, laser treatment, or con-
ventional glaucoma surgery. Since phacoemulsification cataract
surgery is known to reduce IOP (Mansberger 2012), we planned
to examine the effect of the intervention in people who had pha-
coemulsification at the same time compared to people who did
not have phacoemulsification at the same time.
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Types of outcome measures
We did not use the reporting of particular outcomes as a criterion
for eligibility for this review. We did not exclude studies from this
review solely on the grounds of an outcome of interest not being
reported.
Primary outcomes
The primary outcomewas the proportion of participants whowere
drop-free (not using eye drops) at two years after randomisation.
Several different glaucoma outcome measures have been specified
as primary outcomes in other Cochrane Reviews and Protocols
(Ismail 2015). A recent study classified IOP, visual field, safety
and anatomic outcomes as being highly important to glaucoma
experts (Ismail 2016). A panel of patients from the Patient and
Public Involvement Group of the National Institute for Health
Research (NIHR) Biomedical Research Centre for Ophthalmol-
ogy identified drop-free disease control as a highly valued outcome
(unpublished). We chose a patient-centred primary outcome.
Secondary outcomes
Secondary outcomes were:
1. Mean change in IOP, measured using Goldmann
applanation tonometry, from randomisation to two years.
2. The proportion of participants experiencing intra- and
postoperative complications from randomisation to two-year
follow-up including but not restricted to the following:
i) loss of visual acuity (more than 2 Snellen lines or more
than 0.3 logMAR, according to the method of recording visual
acuity; or loss of light perception);
ii) bleeding, as recorded by the investigators;
iii) endophthalmitis, as recorded by the investigators;
iv) IOP spikes (postoperative rise in IOP, measured using
Goldmann applanation tonometry, of more than 10 mmHg
compared to the previous assessment, including during the first
postoperative month);
v) secondary surgery, as recorded by the investigators.
3. Change to any health-related quality of life measures, from
randomisation to two-year follow-up, reported as differences in
means or odds ratios for continuous and binary data, respectively.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (2016, Issue 4), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to May 2016), EMBASE (January 1980 to May 2016), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 12 May 2016.
See Appendices for details of search strategies for CENTRAL (
Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3),
ISRCTN (Appendix 4), ClinicalTrials.gov (Appendix 5), and the
ICTRP (Appendix 6).
Searching other resources
We planned to search the reference lists of included studies for
other possible studies and to contact any individuals or organi-
sations whom we believed may have conducted or be conduct-
ing relevant RCTs. We also searched the website of the manufac-
turer (NeoMedix Inc., Tustin, California; www.trabectome.com)
for any information on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors independently screened titles and abstracts of
all articles identified by the search.Where abstracts were not avail-
able, we planned to screen full-text articles. Two review authors
would independently assess full-text reports of all potentially eli-
gible studies. In case of disagreement regarding eligibility, a third
review author would arbitrate. If we rejected any full-text reports,
we would record the reasons for this.
Data extraction and management
We planned to extract data from reports of included studies using
a data collection form, which was to be developed and piloted on
the first five studies included. Two review authors would indepen-
dently extract study characteristics from reports of each study and
enter the data into RevMan (RevMan 2014). In case of disagree-
ment, a third independent review author would arbitrate.
We planned to collect the following information on the charac-
teristics of included studies (Appendix 7).
• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
• Eligibility criteria.
• Diagnostic criteria.
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• Method of randomisation.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the
intervention.
We planned to collect the following data regarding outcomes (
Appendix 7).
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies were missing or unclear, we
planned to contact the individuals or organisations involved to
obtain clarification. We intended to collect and use the most de-
tailed numerical data available to facilitate analyses of included
studies. We would attempt to obtain this data from individuals or
organisations in preference to less precise methods such as extract-
ing numeric data from graphs. If this was necessary, two review
authors would independently extract the data, and a third review
author would arbitrate in case of disagreement.
Assessment of risk of bias in included studies
We planned to use the latest version of the Cochrane ’Risk of
bias’ tool as described in Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions to assess the risk of bias and
assign judgements of this for included studies (Higgins 2011).
Measures of treatment effect
The primary outcomewas the proportion of participants drop-free
at two years after randomisation. We planned to use an odds ratio
as the treatment effectmeasure. In assessing this effectmeasure, we
planned to report how the prescribing of IOP-lowering eye drops
was determinedduring follow-up.Weplanned to examinewhether
the peoplemeasuring IOPand those decidingupon the prescribing
of IOP-lowering eye drops were masked to the treatment group.
We planned to report mean change in IOP from randomisation to
two years after randomisation. We would report secondary safety
outcomes as odds ratios. We would report health-related quality of
life outcomes as differences in means or odds ratios for continuous
and binary data, respectively.
Unit of analysis issues
We planned to assess whether included studies have included one
or two eyes from each participant and whether or not randomi-
sation had been conducted at the level of the participant or the
eye. There is a potential for medical treatments, such as topical
beta blockers, used for one eye to influence the outcome in the
other eye (Piltz 2000). We therefore planned to exclude studies
that adopted a paired design. Surgery to lower IOP in one eyemay
also affect the IOP of the fellow eye (Radcliffe 2010).
Dealing with missing data
We planned to minimise missing outcome data by contacting in-
dividuals and organisations to try to obtain them. If the data were
unavailable, but the level ofmissing data in each group and reasons
for missing data in each group were similar, we may simply anal-
yse available-case data if an intention-to-treat (ITT) analysis had
not been performed. If the authors had conducted their own ITT
analysis despite missing data we planned to document whether
they provided any justification for the method they had used to
deal with missing data and whether they had compared their ITT
result with an available-case result.
Assessment of heterogeneity
We planned to assess heterogeneity between trials by careful exam-
ination of the study reports, assessing forest plots, and an exami-
nation of the I2 value with its confidence interval. We would con-
sider I2 values greater than 50% as indicative of substantial het-
erogeneity and, therefore, suggestive that meta-analysis might not
be wise; however, we would give consideration to the consistency
of the effect estimates. If all estimates were in the same direction,
we might meta-analyse even where heterogeneity was evident and
comment on the heterogeneity.
Assessment of reporting biases
We planned to use a funnel plot to assess the risk of publication
bias if we included more than 10 trials in the review.
Data synthesis
We planned to undertake a meta-analysis where data appeared
clinically, methodologically, and statistically homogeneous. We
would check that participants, interventions, comparators, and
outcomes were sufficiently similar to give a clinically meaningful
result and that our I2 result indicated little inconsistency (that
is I2 less than 50%). If all estimates were in the same direction,
we might meta-analyse even where heterogeneity was evident but
would comment on this. We planned to use a random-effects
model unless there were fewer than three eligible studies, in which
case we would use a fixed-effect model.
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Subgroup analysis and investigation of heterogeneity
We planned to undertake a subgroup analysis. The effect modi-
fier to be examined was the use of phacoemulsification as a co-
intervention. Phacoemulsification has been shown to reduce IOP
(Mansberger 2012). We would therefore analyse whether the ef-
fect of Trabectome surgery differed depending on whether pha-
coemulsification had been used as a co-intervention.
Sensitivity analysis
We planned to assess the impact of including studies at high risk
of bias.
Summary of findings
We planned to prepare tables to summarise the findings of the
review, including the assessment of the quality of evidence for
all outcomes using the GRADE approach (Langendam 2013).
We were to report all outcomes considered in the review in the
summary.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 155 references (Figure
1). The Cochrane Information Specialist removed 41 duplicate
records, and two review authors (GG and KH) independently
screened the remaining 114 reports for potentially eligible studies,
namely possible RCTs.
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Figure 1. Study flow diagram.
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There was no disagreement between the authors regarding eligi-
bility of any of the search results. We assessed no full-text reports,
however we identified one ongoing trial as potentially relevant (see
Characteristics of ongoing studies).
We are not aware of any other individuals or organisations who
have conducted or may be conducting relevant RCTs. A search
of the website of the manufacturer (NeoMedix Inc., Tustin, Cal-
ifornia; www.trabectome.com) did not yield any information on
forthcoming trials.
Included studies
Wedidnot find any publishedRCTs thatmet the inclusion criteria.
Excluded studies
We did not exclude any trials after obtaining the full-text report.
Ongoing studies
One RCT, NCT00901108, met the criteria for inclusion. How-
ever, at the time of the original search for this review, it was an
ongoing study recruiting participants and had not yet been pub-
lished. This trial compares combined Trabectome and cataract ex-
traction with intraocular lens implantation against combined tra-
beculectomy with mitomycin C and cataract extraction with in-
traocular lens insertion. We note that the listing on ClinicalTri-
als.gov has subsequently been updated (8 June 2015) to indicate
that enrolment to the study was closed early owing to “lack of clin-
ical equipoise essential for patient randomisation/recruitment”.
The investigators planned to complete 12 months of follow-up
and analysis on participants already recruited into the trial. On 23
February 2016 the ClinicalTrials.gov record was updated noting
that: “A total of 19 participants were recruited with follow up to
one year. Study analysis is pending.” For further information on
this study, see the Characteristics of ongoing studies table.
Risk of bias in included studies
We have included no trials in this review for reasons previously
mentioned.
Effects of interventions
There were no completed RCTs reporting the outcomes of ab
interno trabeculotomy performed with the Trabectome for open
angle glaucoma.
D I S C U S S I O N
There are currently no RCTs reporting the outcomes of ab interno
trabecular bypass surgery with Trabectome for open angle glau-
coma.
One RCT is in progress. Enrolment to this trial was closed early,
which will reduce its power to detect differences in safety and
efficacy. The trial will report outcomes up to 12 months of follow-
up, but not more long-term outcomes.
Summary of main results
There are currently no RCTs providing evidence for the outcomes
of ab interno trabecular bypass surgery with Trabectome for open
angle glaucoma.
Overall completeness and applicability of
evidence
Webelieve that our conclusions are supported by a thorough search
of available evidence, as outlined in the published protocol (Hu
2015).
Quality of the evidence
We did not identify any trials for inclusion in this review.
Potential biases in the review process
The review authors may not be aware of individuals or organisa-
tions who have conducted or may be conducting relevant RCTs,
therefore it is possible that relevant RCTs have not been identified.
Agreements and disagreements with other
studies or reviews
A review examining IOP and glaucoma medications following ab
interno trabecular bypass surgery with Trabectome was published
recently (Kaplowitz 2016). This review included only prospective
or retrospective case series or cohorts, so the results are not com-
parable with our review.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
There is currently no high-quality evidence for the outcomes of
ab interno trabecular bypass surgery with Trabectome for open
angle glaucoma. Practitioners need to take this into account when
considering treatment options for open angle glaucoma.
Implications for research
Ab interno trabecular bypass surgery with Trabectome has been
used for over 10 years. Properly designed RCTs are needed to
assess the long-term efficacy and safety of this technique compared
to conventional glaucoma treatments for people with open angle
glaucoma. These RCTs should assess outcomes that are relevant
to patients, such as freedom from using eye drops. If superiority is
demonstrated compared to conventional treatments, the next step
would be to determine whether Trabectome is superior to other
forms of minimally invasive glaucoma surgery.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of ongoing studies [ordered by study ID]
NCT00901108
Trial name or title Trabectome versus trabeculectomy with mitomycin C in patients with open angle glaucoma
Methods Single-centre, single-surgeon, parallel-group randomised controlled trial with 2 study arms
1 eye included in study (method of selection not specified)
Originally intended to recruit 52 participants (26 participants per study arm). However, recruitment was
closed early (total recruitment = 19) owing to “clearer indications for each technique over time leading to
lack of clinical equipoise essential for patient randomization/recruitment”
Participants Characteristics of participants are unknown. Total number of participants recruited is 19
Inclusion criteria:
1. Age 40 to 85 years
2. Open angle glaucoma (including pseudo exfoliative glaucoma)
3. Open angles (≥ Shaffer grade II)
4. Inadequately controlled IOP requiring surgical intervention
5. Visually significant cataract
6. Willing to complete quality of life questionnaires
7. Capable of informed consent and available for at least 1 year follow-up
Exclusion criteria:
1. Any form of angle-closure glaucoma
2. Secondary open angle glaucomas
3. Absence of clear angle landmarks on gonioscopy
4. Other ocular disease that may affect assessments of visual acuity, visual field, or accurate tonometry
5. Previous angle surgery or filtering procedure
6. Steroid use within the preceding 3 months
7. Presence of significant comorbidities
Interventions Trabectome-IOL: Combined Trabectome and cataract extraction with intraocular lens insertion (n = un-
known)
Trab-IOL: Combined trabeculectomy with mitomycin C and cataract extraction with intraocular lens inser-
tion (n = unknown)
Outcomes Primary outcome measures:
• Mean IOP at 6 months
• Surgical complication rates (Time Frame: intraoperative and postoperative up to 12 months)
Secondary outcome measures:
• Mean difference in IOP from baseline to 6 months
• Mean IOP at 12 months
• Quality of life measures (Time Frame: preoperative and postoperative at 6 and 12 months)
• Mean number of glaucoma medications (Time Frame: 12 months)
• Visual acuity (Time Frame: 12 months)
• Need for additional laser (excluding suture lysis) and surgical interventions (Time Frame: 12 months)
Starting date November 2009
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NCT00901108 (Continued)
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees
#2 MeSH descriptor: [Intraocular Pressure] explode all trees
#3 MeSH descriptor: [Ocular Hypertension] explode all trees
#4 OAG or POAG or IOP or OHT
#5 simple near/3 glaucoma*
#6 open near/2 angle near/2 glaucoma*
#7 chronic near/2 glaucoma*
#8 secondary near/2 glaucoma*
#9 low near/2 tension near/2 glaucoma*
#10 low near/2 pressure near/2 glaucoma*
#11 normal near/2 tension near/2 glaucoma*
#12 normal near/2 pressure near/2 glaucoma*
#13 pigment near/2 glaucoma*
#14 MeSH descriptor: [Exfoliation Syndrome] this term only
#15 exfoliat* near/2 syndrome*
#16 exfoliat* near/2 glaucoma*
#17 pseudoexfoliat* near/2 syndrome*
#18p seudoexfoliat* near/2 glaucoma*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 trabectome
#21 ab interno trabeculectomy or trabeculectomy ab interno
#22 ab interno trabeculotomy or trabeculotomy ab interno
#23 trabecular near/2 bypass*
#24 #20 or #21 or #22 or #23
#25 #19 and #24
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp glaucoma open angle/
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14. exp intraocular pressure/
15. ocular hypertension/
16. (OAG or POAG or IOP or OHT).tw.
17. (simple$ adj3 glaucoma$).tw.
18. (open adj2 angle adj2 glaucoma$).tw.
19. (primary adj2 glaucoma$).tw.
20. (chronic adj2 glaucoma$).tw.
21. (secondary adj2 glaucoma$).tw.
22. (low adj2 tension adj2 glaucoma$).tw.
23. (low adj2 pressure adj2 glaucoma$).tw.
24. (normal adj2 tension adj2 glaucoma$).tw.
25. (normal adj2 pressure adj2 glaucoma$).tw.
26. (pigment$ adj2 glaucoma$).tw.
27. exfoliation syndrome/
28. (exfoliat$ adj2 syndrome$).tw.
29. (exfoliat$ adj2 glaucoma$).tw.
30. (pseudoexfoliat$ adj2 syndrome$).tw.
31. (pseudoexfoliat$ adj2 glaucoma$).tw.
32. or/13-31
33. trabectome.tw.
34. (Ab interno adj2 (trabeculectomy or trabeculotomy)).tw.
35. (trabecular adj2 bypass$).tw.
36. or/33-35
37. 32 and 36
38. 12 and 37
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
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24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. open angle glaucoma/
34. intraocular pressure/
35. intraocular hypertension/
36. (OAG or POAG or IOP or OHT).tw.
37. (open adj2 angle adj2 glaucoma$).tw.
38. (primary adj2 glaucoma$).tw.
39. (chronic adj2 glaucoma$).tw.
40. (secondary adj2 glaucoma$).tw.
41. (low adj2 tension adj2 glaucoma$).tw.
42. (low adj2 pressure adj2 glaucoma$).tw.
43. (normal adj2 tension adj2 glaucoma$).tw.
44. (normal adj2 pressure adj2 glaucoma$).tw.
45. (pigment$ adj2 glaucoma$).tw.
46. exfoliation syndrome/
47. (exfoliat$ adj2 syndrome$).tw.
48. (exfoliat$ adj2 glaucoma$).tw.
49. (pseudoexfoliat$ adj2 syndrome$).tw.
50. (pseudoexfoliat$ adj2 glaucoma$).tw.
51. or/33-50
52. trabectome.tw.
53. (ab interno adj2 (trabeculectomy or trabeculotomy)).tw.
54. (trabecular adj2 bypass$).tw.
55. or/52-54
56. 51 and 55
57. 32 and 56
Appendix 4. ISRCTN search strategy
trabectome OR trabecular bypass OR ab interno trabeculectomy OR ab interno trabeculotomy
Appendix 5. ClinicalTrials.gov search strategy
(trabectome OR trabecular bypass OR ab interno trabeculectomy OR ab interno trabeculotomy)
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Appendix 6. ICTRP search strategy
trabectome OR trabecular bypass OR ab interno trabeculectomy OR ab interno trabeculotomy = Intervention
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design · Parallel-group RCT i.e. people ran-
domised to treatment
· Within-person RCT i.e. eyes randomised
to treatment










How were missing data handled? e.g. avail-
able-case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes
Unit of randomisation/unit of analysis
· 1 eye included in study, specify how eye
selected
· 2 eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within-person correlation/both
and not adjusted for within-person correla-
tion) and specify if mixture of 1 eye and 2 eyes
· 2 eyes included in study, eyes received







Equivalence of baseline characteristics (Y/
N)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate
Number (%) of men and women




Intervention (n = )
Comparator (n = )
· Number of people randomised to this
group
· Intervention name
Trabectome surgical parameters, e.g. degrees
of meshwork ablated, electrosurgical power
Comparator parameters, e.g. dosage of drugs
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(Continued)
· Comparator name
· Specify whether phacoemulsification or
other intervention performed at same time
as intervention
Outcomes
Primary and secondary outcomes as defined
in study reports
· IOP at baseline
· IOP at follow-up
·Number of glaucomamedications at base-
line
· Number of glaucoma medications at fol-
low-up
· Intraoperative complications
· Postoperative complications or secondary
surgery
· Duration of follow-up
· Loss to follow-up
· Intervals at which outcomes assessed
Adverse events reported (Y/N)
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Date of publication
Reported subgroup analyses (Y/N)
Were trial investigators contacted?Sources of funding -
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